Sign in
Enrolling by invitationNo phase

Compares an SGLT2 inhibitor with other diabetes pills in atrial fibrillation

Compares an SGLT2 inhibitor with other diabetes pills in adults with atrial fibrillation and diabetes.

Key facts

Who runs it
Ewha Womans University Mokdong Hospital
Where
Yangcheon, South KoreaSee the site
Trial code
Registry title
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
Status
Enrolling by invitation
People taking part
716 people, planned
Started
5 Oct 2021
Expected to end
Dec 2026
Type of study
Observational, 2 groups
Treatments tested
  • SGLT2 inhibitor
Record updated
23 January 2023

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 20 to 80 with type 2 diabetes who had atrial fibrillation in the past year and take only oral diabetes medicines.

Age
20 to 80 years
Sex
All sexes can join.
Disease stage
At least one atrial fibrillation episode recorded on an ECG in the past year. Type 2 diabetes with HbA1c above 6.5% (48 mmol/mol). Normal ECG measurements while in normal heart rhythm.
Earlier treatment
Only oral diabetes medicines are used. Previous treatment with any SGLT2 inhibitor or with AF ablation is not allowed. Treatment with insulin is not allowed.
Biomarker or test result
HbA1c above 6.5% (48 mmol/mol) at diagnosis (type 2 diabetes).

Main reasons for not taking part

  • Illness that limits life expectancy to under 1 year
  • Pregnant or breastfeeding women
  • Type 2 diabetes treated with recombinant insulin, or type 1 diabetes, MODY or secondary diabetes
  • Kidney problems (eGFR under 30 ml/min/1.73 m²)
  • Heart attack, stroke or other acute heart event less than 8 weeks ago, or severe valve disease or a prosthetic valve

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • At least one episode of atrial fibrillation* that is documented during the prior year by any kind of ECG recording
  • Diabetes mellitus type II was diagnosed. (HBA1c >6.5%) and are using oral hypoglycemic agents only
  • At least 20 years old and not older than 80 years old
  • Normal ECG parameters when measured in sinus rhythm (QRS width ≤120 ms, QTc interval <440 ms, and PQ interval ≤210 ms in a 12 lead ECG)
  • Able and willing to give informed consent

Who cannot take part

  • Drug abuser
  • Previous treatment with any SGLT2 inhibitor
  • Previous treatment with AF ablation
  • Acute cardiovascular event [e.g., stroke, acute coronary syndrome (ACS), revascularization, decompensated HF, sustained ventricular tachycardia, return of spontaneous circulation (ROSC)] <8 weeks prior to baseline study
  • Treatment with chronic oral steroid (>30 consecutive days) at a dose equivalent to oral prednisolone ≥10mg/d, within the past 1 month
  • Any disease that limits life expectancy under 1 year
  • Chronic cystitis and/or recurrent genitourinary tract infections (3 or more in the last year)
  • Severe valvular disease or have prosthetic valve
  • History of any malignancy within 5 years
  • Patients incapable of completing the trial due to any severe medical condition by clinical decision
  • HbA1c ≥12% or HbA1c <6.5% at diagnosis
  • Renal dysfunction (eGFR-CKD-EPI <30ml/min/1.73m\^2)
  • Under 20 years old or over 80 years old
  • Subject for another clinical trial within the past 2 months
  • Pregnant women
  • Lactating women
  • Type 2 DM treated by recombinant insulin
  • Diagnosis of Type 1 DM, MODY, or secondary DM
  • Unexplained hematuria at baseline study
  • Systolic BP >180mmHg or diastolic BP >100mmHg at baseline study
  • Systolic BP <95mmHg at baseline study
  • Clinically profound hepatic dysfunction
  • Clinically uncontrolled thyroid dysfunction
  • Patients with poor compliance (defined as 80 - 120%), except for reasonable situations judged by physician

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 20 and 80 years old?

Where in South Korea

  • Ewha womans university mokdong hospitalYangcheon, South KoreaEnrolling by invitation

About the trial

What the trial wants to find out

This study was designed to compare the effects on atrial rhythm control between SGLT2 inhibitor and other oral hypoglycemic agents in patients with atrial fibrillation and diabetes mellitus. We are to compare efficacy and safety between these two groups.

The 2 groups in the trial

  • SGLT-2 inhibitor administration group

    The group who administrated SGLT-2 inhibitor for hypoglycemic medication

    Treatment: SGLT2 inhibitor

  • control

    The group who are not administrated SGLT-2 inhibitor

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
Plain-language title
Compares an SGLT2 inhibitor with other diabetes pills in atrial fibrillationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05029115, who can take part
Publications
Record updated
23 January 2023